Yesafili, an interchangeable biosimilar to Eylea 2 mg, is now commercially available in the United States, according to a press release from Biocon.
August 03, 2026
1 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili™, a Biosimilar to Eylea® (Aflibercept)
Biocon's stock rises 1.22% as clinical data for Yesafili biosimilar is published, marking a key milestone for the company.
The FDA approved Ranluspec, an interchangeable biosimilar referencing Lucentis, as a treatment for vision-threatening retinal…
Atea's BEM/RZR matches Gilead's Epclusa in Phase 3; AbCellera partners with Vertex for $28M; LB Pharma raises $150M for…
Bispecific antibody fares well against faricimab, two gene therapies extend treatment intervals
Two of ivonescimab’s biggest competitors are releasing new data in Chicago: pumitamig, from BioNTech and Bristol Myers Squibb;…
Atea's hep C pill equal to Gilead's; AbCellera inks second deal in two months
Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate
Biocon gets Health Canada nod for Yesintek autoinjector pen
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate
Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat
Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market
